8-Dec-2025
Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences
Globe Newswire (Mon, 3-Nov 8:00 AM ET)
LQDA Turns Profitable as YUTREPIA Drives Record Revenue and Operating Income in First Full Quarter
Market Chameleon (Mon, 3-Nov 2:09 AM ET)
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Globe Newswire (Mon, 3-Nov 6:30 AM ET)
Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025
Globe Newswire (Mon, 27-Oct 8:30 AM ET)
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025
Globe Newswire (Tue, 7-Oct 6:32 AM ET)
Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting
Globe Newswire (Mon, 29-Sep 8:30 AM ET)
Globe Newswire (Thu, 11-Sep 8:30 AM ET)
Market Chameleon (Tue, 12-Aug 6:35 AM ET)
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Liquidia trades on the NASDAQ stock market under the symbol LQDA.
As of December 8, 2025, LQDA stock price climbed to $35.01 with 1,188,068 million shares trading.
LQDA has a beta of 1.84, meaning it tends to be more sensitive to market movements. LQDA has a correlation of 0.19 to the broad based SPY ETF.
LQDA has a market cap of $3.01 billion. This is considered a Mid Cap stock.
Last quarter Liquidia reported $54 million in Revenue and -$.04 earnings per share. This beat revenue expectation by $37 million and exceeded earnings estimates by $.34.
In the last 3 years, LQDA traded as high as $35.23 and as low as $5.20.
The top ETF exchange traded funds that LQDA belongs to (by Net Assets): IWM, VTI, IWO, VXF, SCHA.
LQDA has outperformed the market in the last year with a price return of +205.0% while the SPY ETF gained +13.9%. LQDA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +21.4% and +20.3%, respectively, while the SPY returned +5.9% and +3.7%, respectively.
LQDA support price is $32.96 and resistance is $35.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LQDA shares will trade within this expected range on the day.